CDKN1B antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | cyclin-dependent kinase inhibitor 1B(p27, Kip1) (CDKN1B) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | WB: 1:200-1:2000; IP: 1:200-1:1000; IHC: 1:50-1:500; IF: 1:50-1:500 |
| Clonality | polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | 27 kDa |
| Purity | ≥95% as determined by SDS-PAGE |
| Purification | Immunogen affinity purified |
| Size 1 | 100µg |
| Form | liquid |
| Tested Applications | ELISA, WB, IP, IHC, IF |
| Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
| UniProt ID | P46527 |
| Gene ID | 1027 |
| Alias | Cyclin-dependent kinase inhibitor 1B,Cyclin-dependent kinase inhibitor p27,p27Kip1,CDKN1B,KIP1,p27 |
| Background | Antibody anti-CDKN1B |
| Status | RUO |
| Note | Mol. Weight 27 kDa |
Descripción
Related Products
Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
CDKN1B antibody
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Ver Producto